A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2023-08-23
Adverse events
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-12-30 (study day 118); relationship: Y
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-02-06 (study day 156); relationship: not assessed
Grade 1 Alopecia — outcome: UNKNOWN; onset 2024-03-02 (study day 181); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-07-12 (study day 313); relationship: Y
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-09-06 (study day 369); relationship: not assessed
Data queries
No data queries.